Tutorials › Quantitative Systems Pharmacology (QSP) › Chronic Antigen Exposure and T-Cell Exhaustion

Immuno-Oncology: Checkpoint Inhibitors and Cell Therapy · Tutorial 278 of 799

Chronic Antigen Exposure and T-Cell Exhaustion

Build and interpret models linking sustained antigen stimulation to reversible or persistent loss of T-cell function.

Advanced 11 min read

What You'll Learn

  • Define an antigen-dependent transition model for a normalized active and exhausted T-cell pool.
  • Derive its steady-state exhaustion level and time course under constant antigen drive.
  • Translate an exhaustion burden into a normalized functional-capacity measure.
  • Calculate functional decline during persistent stimulation and recovery after withdrawal.
  • Distinguish reversible impairment from a durable residual loss in model structure.
  • Check assumptions and identify data patterns that challenge a proposed model.

Why Duration of Antigen Exposure Matters

T cells can become less functional when stimulation persists. In a quantitative systems pharmacology model, this phenomenon can be represented as a time-dependent change in functional state: ongoing antigen exposure increases the rate at which cells enter an impaired state, while reduced stimulation may permit some recovery. The distinction between reversible impairment and durable loss matters because the same antigen signal can produce different predictions after stimulation falls, depending on the model’s recovery assumptions.

This tutorial focuses on that relationship, not on a detailed taxonomy of T-cell subsets. An exhaustion state in a model is an operational representation of reduced function under sustained stimulation; it is not established simply by observing one marker, and it need not correspond to a single biological cell type. Earlier material on T-cell activation and PD-1 pathway suppression provides context for why stimulation and inhibitory signals may change over time. Here, the central modeling question is how to represent the accumulated functional consequence.

A Reversible State-Transition Model

Let \(A(t)\) and \(E(t)\) be the fractions of a fixed, normalized T-cell pool in an active and an impaired state, respectively. In this minimal model, \(A(t)+E(t)=1\). The model tracks state composition, not total T-cell abundance: it omits cell proliferation, death, trafficking, and changes in antigen presentation. Those omissions are assumptions, not claims that these processes are biologically unimportant.

Definition: Let \(C(t)\) be the antigen concentration, \(EC_{50}\) the concentration producing half-maximal antigen drive, and \(a(t)=C(t)/(EC_{50}+C(t))\) the dimensionless antigen drive. Let \(k_{\mathrm{ex}}\) be the maximum active-to-impaired transition rate and \(k_{\mathrm{rec}}\) the maximum recovery rate, both in day\(^{-1}\). The reversible model is
$$ \frac{dE}{dt} = k_{\mathrm{ex}}a(t)(1-E) - k_{\mathrm{rec}}[1-a(t)]E, \qquad A(t)=1-E(t). $$

The first term moves active cells into the impaired state, with a rate that increases with antigen drive. The second term returns impaired cells to the active state, with recovery favored as antigen drive decreases. This is a deliberately simple phenomenological structure. In particular, \(a(t)\) is an assumed effective drive, not a direct measurement of every signal that may contribute to dysfunction.

The model assumes that the normalized pool is closed, the transition rates are nonnegative, and the same antigen drive acts on all cells in the pool. It also assumes that an impaired cell can recover according to the specified rate. If the data show loss of total T-cell number, strong cell-to-cell heterogeneity, or a persistent impairment that remains after antigen withdrawal, this model alone may be inadequate.

Constant Antigen: Steady State and Time Course

For constant antigen drive \(a\), collect the terms in \(E\):

$$ \frac{dE}{dt} = k_{\mathrm{ex}}a - \{k_{\mathrm{ex}}a+k_{\mathrm{rec}}(1-a)\}E. $$

Writing \(\lambda=k_{\mathrm{ex}}a+k_{\mathrm{rec}}(1-a)\), for \(\lambda>0\) the solution approaches a steady state \(E_{\mathrm{ss}}\). At steady state, \(dE/dt=0\), so \(k_{\mathrm{ex}}a=\lambda E_{\mathrm{ss}}\). If \(\lambda=0\), both transition terms are zero, \(E(t)=E(0)\), and every value of \(E\) is steady. Therefore,

$$ \begin{cases} E_{\mathrm{ss}} = \frac{k_{\mathrm{ex}}a} {k_{\mathrm{ex}}a+k_{\mathrm{rec}}(1-a)}, \qquad E(t)=E_{\mathrm{ss}}+[E(0)-E_{\mathrm{ss}}]e^{-\lambda t}, & \lambda>0,\\ E(t)=E(0),\qquad E_{\mathrm{ss}}\text{ may be any constant}, & \lambda=0. \end{cases} $$

This derivation also shows what controls the speed of adjustment when \(\lambda>0\): the time constant is \(1/\lambda\), in days. A larger \(\lambda\) makes the model approach its steady state more quickly. When \(a=0\), \(E_{\mathrm{ss}}=0\) if \(k_{\mathrm{rec}}>0\), and impairment decays at rate \(k_{\mathrm{rec}}\). When \(a=1\) and \(k_{\mathrm{ex}}>0\), recovery is zero in this formulation and the impaired fraction approaches one. These limiting cases follow from the chosen model structure and should be checked against the intended biological interpretation.

Worked Example: Estimating the Impaired Fraction Under Sustained Antigen

Consider a hypothetical normalized T-cell pool with constant antigen drive \(a=0.80\), \(k_{\mathrm{ex}}=0.12\) day\(^{-1}\), and \(k_{\mathrm{rec}}=0.030\) day\(^{-1}\). Suppose \(E(0)=0.10\). Calculate the impaired fraction after 20 days and the functional-capacity factor if each impaired cell retains 20% of the activity of an active cell.

The constant-drive assumption is explicit in the scenario. The model’s normalized pool has no birth, death, or exchange, so \(A+E=1\) remains true. First calculate the approach rate and steady state:

$$ \lambda=(0.12)(0.80)+(0.030)(0.20)=0.096+0.006=0.102\ \text{day}^{-1}, $$
$$ E_{\mathrm{ss}}=\frac{(0.12)(0.80)}{0.102} =\frac{0.096}{0.102} =0.9412. $$

The time-course solution gives

$$ \begin{aligned} E(20) &=0.9411765+(0.10-0.9411765)e^{-(0.102)(20)}\\ &=0.9411765-0.8411765e^{-2.04}\\ &\approx0.9411765-(0.8411765)(0.1300)\\ &\approx0.8318. \end{aligned} $$

Thus, the model predicts that about 83.18% of this normalized pool is in the impaired state at day 20. Let \(q=0.80\) denote the fractional loss of activity in the impaired state: an impaired cell retains \(1-q=0.20\) of active-cell activity. The pool-level functional-capacity factor is \(g=1-qE\), so

$$ g=1-(0.80)(0.8318)\approx0.3346. $$

The predicted capacity is about 0.3346 of the all-active reference capacity. It is a normalized model output, not a measured clinical response or a statement that each cell has identical function.

Functional Decline as a Simpler Alternative

A model need not explicitly track active and impaired fractions if the available data only support a functional summary. One option is to represent an exhaustion burden \(f(t)\), scaled from zero to one, that approaches a limiting level under constant stimulation. The parameter \(f_{\infty}\) is the long-run burden at the specified stimulation, \(f_0\) is its value at the start of the interval, and \(k\) is an approach rate in day\(^{-1}\):

$$ f(t)=f_{\infty}+(f_0-f_{\infty})e^{-kt}. $$

This expression is the solution of \(df/dt=k(f_{\infty}-f)\) for constant conditions. A functional-capacity factor can then be defined as \(g=1-qf\), where \(q\) specifies how strongly the burden reduces function. The formula is compact and estimable from longitudinal functional data, but it does not distinguish entry into impairment from recovery as separate processes. Its limiting value also applies only under the conditions represented during the fitted interval.

Worked Example: Functional Capacity During Persistent Stimulation

For a hypothetical functional-decline model, suppose \(f_0=0.1000\), \(f_{\infty}=2/3\), \(k=0.0600\) day\(^{-1}\), and \(q=0.80\). Calculate the burden and capacity after 20 days of persistent stimulation. These values are assumed model inputs; the example does not describe an observed study.

Substitute the inputs into the exponential solution. Using \(e^{-1.2}=0.3011942\),

$$ \begin{aligned} f(20) &=\frac{2}{3}+\left(0.1000-\frac{2}{3}\right)e^{-(0.0600)(20)}\\ &\approx0.6666667-(0.5666667)(0.3011942)\\ &\approx0.4959899\\ &\approx0.4960. \end{aligned} $$

The associated capacity factor is

$$ g=1-(0.80)(0.4959899)=0.6032081\approx0.6032. $$

The result means that, under this model and its scaling, capacity is about 60.32% of the reference capacity at day 20. It does not imply that there is a 60.32% probability of a clinical response.

Recovery and Durable Impairment

A purely reversible model predicts recovery according to its specified recovery rate when antigen drive falls. If functional measurements instead show a persistent residual deficit, one representation is to add a nonrecovering component to the functional burden. For example, after stimulation is withdrawn, write \(f(t)=f_d+[f(0)-f_d]e^{-k_{\mathrm{rec}}t}\), where \(f_d\) is the residual burden over the modeled follow-up. The quantity \(f_d\) is an empirical floor under those conditions; without additional biological evidence, it should not be interpreted as a uniquely identified cell state or mechanism.

Worked Example: Estimating Residual Impairment After Withdrawal

In a hypothetical system, antigen stimulation is withdrawn at time zero. The functional burden is \(f(0)=0.6000\), the assumed residual floor is \(f_d=0.2000\), and recovery toward that floor occurs at \(k_{\mathrm{rec}}=0.0400\) day\(^{-1}\). Find the burden after 30 days and the capacity factor for \(q=0.80\).

This calculation assumes that the antigen drive remains withdrawn, the recovery rate is constant, and the residual floor does not change over the 30-day period. Then \(e^{-(0.0400)(30)}=e^{-1.2}=0.3011942\), giving

$$ \begin{aligned} f(30) &=0.2000+(0.6000-0.2000)e^{-1.2}\\ &=0.2000+(0.4000)(0.3011942)\\ &=0.3204777\approx0.3205. \end{aligned} $$

The capacity factor is

$$ g=1-(0.80)(0.3204777)=0.7436178\approx0.7436. $$

The model predicts recovery toward, but not beyond, the specified residual burden: as time increases, \(f(t)\) approaches 0.2000. Estimating that floor requires measurements that extend sufficiently far into the post-stimulation period; a short follow-up may not distinguish a true residual from slow recovery.

Choosing a Representation and Checking It

The state-transition model is useful when the data or mechanistic question require separate rates for impairment and recovery. The functional-decline model is more parsimonious when the main evidence is a changing functional readout and separate transition rates cannot be identified. Both are alternatives to a constant-function assumption, which may be reasonable over a short interval but cannot represent accumulated exposure effects. Neither form, by itself, establishes the biological cause of dysfunction.

Before interpreting a fit, check that its assumptions agree with the observations. Useful diagnostics include plotting measured function and model predictions over time, examining residuals for systematic trends, and comparing predictions during persistent stimulation with those after antigen reduction or withdrawal. A model that fits only the stimulation phase may have an unsupported recovery rate. Likewise, if measured T-cell counts fall while the model fixes the pool size, a change in state fractions may be mistaken for cell loss.

  • Check bounds and direction. With nonnegative rates and \(0\leq a\leq1\), the transition model should keep \(E\) between zero and one. Predictions outside that range signal an implementation or parameterization problem.
  • Check time units. A rate in day\(^{-1}\) must be paired with time in days. Mixing hours and days changes the predicted trajectory.
  • Check identifiability. A single functional time course may not determine \(k_{\mathrm{ex}}\), \(k_{\mathrm{rec}}\), \(q\), and antigen drive separately. Distinct parameters can produce similar predicted capacity.
  • Check for a missing residual. Persistent impairment after withdrawal may contradict a model that forces complete recovery. Conversely, a nonzero fitted floor is not proof of irreversible exhaustion if follow-up is short.

A common mistake is to interpret a high exhaustion burden as evidence that all T cells have permanently lost function. In the reversible transition model, \(E\) is a fraction in an operational state, and its future depends on the recovery term. In the residual-floor model, \(f_d\) represents a persistent component only within the observation window and assumptions. Neither quantity alone establishes permanence, cell identity, or a causal mechanism.

Key takeaway: Persistent antigen can be represented as increasing entry into an impaired state or as driving a functional burden toward a limiting level. State transitions separate impairment and recovery rates; a functional model is simpler but less mechanistically specific. Durable loss requires evidence that a residual deficit persists beyond plausible reversible recovery.

Check Your Understanding

Answer each question using the model definitions above. Solutions are included for checking your reasoning.

  1. If \(a=0\) and \(k_{\mathrm{rec}}>0\), what happens to \(E(t)\) in the reversible transition model?
  2. For constant \(a\), explain why the steady-state impaired fraction increases when \(k_{\mathrm{ex}}a\) increases while the recovery term is held fixed.
  3. A model has \(f_d=0.10\) after antigen withdrawal. Does that value prove that 10% of cells occupy a permanently exhausted biological subset? Explain.
  4. Why is it problematic to fit both \(q\) and the impairment burden using only one pool-level functional measurement at one time point?
  5. Suppose \(k=0.05\) day\(^{-1}\) in a functional-decline model. What is the time constant, and what does it describe?

Solutions. (1) With \(a=0\), \(dE/dt=-k_{\mathrm{rec}}E\), so \(E(t)=E(0)e^{-k_{\mathrm{rec}}t}\) and declines toward zero. (2) The steady state is \(x/(x+y)\), where \(x=k_{\mathrm{ex}}a\) and \(y=k_{\mathrm{rec}}(1-a)\). For fixed \(y>0\), its derivative with respect to \(x\) is \(y/(x+y)^2>0\), so the steady-state fraction increases. (3) No. It is a residual burden in the chosen model over the observed conditions and follow-up, not proof of a distinct permanent cell subset. (4) A single pool-level value constrains the product of burden and its functional effect, \(qf\), rather than identifying \(q\) and \(f\) separately. (5) The time constant is \(1/k=20\) days; under constant conditions, it is the characteristic timescale of approach to the model’s limiting burden.

Clinical Biostats